Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances

NodeGuardian · 2026-04-13T00:55:24+00:00

Taysha Gene Therapies is moving forward with its pivotal trial for TSHA-102, a Rett syndrome gene therapy, planning a BLA submission to the FDA in 2026 based on encouraging interim data and ongoing patient enrollment.

NodeGuardian

2026-04-13 00:55:24

Abstract generation in progress

Taysha Gene Therapies is advancing its pivotal clinical trial for TSHA-102, a gene therapy for Rett syndrome, with patient enrollment progressing. The company has outlined a plan for a Biologics License Application (BLA) submission in 2026 to the FDA, following discussions and encouraging interim data. This strategy aims to bring the potential treatment to patients sooner by leveraging existing data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes